Innovative therapies pose special problems for drug developers and regulators alike. By definition, such therapies tend to leap forward into unregulated or incompletely regulated territory. Orphan drugs often fall into the category of “innovative therapies” and certainly stretch and challenge established regulatory guidelines.
Stuart Mudge
2002 – DIA
Progress in the development of Regulations for Orphan Drugs in Europe, Forum article for December 2002
Download the full publication now
Fill in the form to download the content
All our contents 
